Notice | Nanologica

NOTICE OF EXTRAORDINARY GENERAL MEETING IN NANOLOGICA AB (PUBL)

29 August, 2024

The shareholders of Nanologica AB (publ), corp. reg. no 556664-5023 (the “Company”) are hereby convened to an extraordinary general meeting on Monday 23 September 2024, at 12.00, at Redeye’s premises, Mäster Samuelsgatan 42, Stockholm. Right to attend the meetingShareholders who wish to participate in the general meeting must: Be registered in their own name (not nominee-registered) in the share register maintained by Euroclear Sweden AB on Friday 13 September 2024, and Notify the Company of

KALLELSE TILL EXTRA BOLAGSSTÄMMA I NANOLOGICA AB (PUBL)

29 August, 2024

Aktieägarna i Nanologica AB (publ), org.nr 556664-5023 (”Bolaget”) kallas härmed till extra bolagsstämma måndagen den 23 september 2024, klockan 12.00, i Redeyes lokaler, Mäster Samuelsgatan 42, Stockholm. Rätt att delta vid stämmanAktieägare som önskar delta i bolagsstämman ska: dels vara registrerad i eget namn (inte förvaltarregistrerad) i den av Euroclear Sweden AB förda aktieboken fredagen den 13 september 2024, dels anmäla sitt deltagande så att anmälan är Bolaget tillhanda senast onsdagen den 18 september 2024,

Notice Convening the Annual General Meeting of Nanologica AB (publ)

10 April, 2024

The shareholders of Nanologica AB (publ), org.nr 556664-5023 (the "Company") are hereby summoned to the Annual General Meeting on Thursday 16 May 2024, at 12.00 CET, at Redeye's premises at Mäster Samuelsgatan 42, Stockholm. English translation for information purposes only. If there are differences between the English translation and the Swedish original, the Swedish text will take precedence. Right to attend the meetingShareholders who wish to participate in the Annual General Meeting must: be registered

Kallelse till årsstämma i Nanologica AB (publ)

10 April, 2024

Aktieägarna i Nanologica AB (publ), org.nr 556664-5023 (”Bolaget”) kallas härmed till årsstämma torsdagen den 16 maj 2024, klockan 12.00, i Redeyes lokaler på Mäster Samuelsgatan 42, Stockholm. Rätt att delta vid stämmanAktieägare som önskar delta i årsstämman ska: dels vara registrerad i eget namn (inte förvaltarregistrerad) i den av Euroclear Sweden AB förda aktieboken tisdagen den 7 maj 2024, dels anmäla sitt deltagande så att anmälan är Bolaget tillhanda senast måndagen den 13 maj 2024,

NOTICE OF EXTRAORDINARY GENERAL MEETING IN NANOLOGICA AB (PUBL)

30 January, 2024

The shareholders of Nanologica AB (publ), org.nr 556664-5023 (the "Company") are hereby convened to the extraordinary general meeting on Thursday 22 February 2024, at 12.00 p.m. CET, at Hagberg & Aneborn Fondkommissions’ premises, Jungfrugatan 35, Stockholm. Right to attend the meetingShareholders who wish to participate in the extraordinary general meeting must: be registered in their own name (not nominee-registered) in the share register maintained by Euroclear Sweden AB on Wednesday 14 February 2024, and notify

KALLELSE TILL EXTRA BOLAGSSTÄMMA I NANOLOGICA AB (PUBL)

30 January, 2024

Aktieägarna i Nanologica AB (publ), org.nr 556664-5023 (”Bolaget”) kallas härmed till extra bolagsstämma torsdagen den 22 februari 2024, klockan 12.00, i Hagberg & Aneborn Fondkommissions lokaler, Jungfrugatan 35, Stockholm. Rätt att delta vid stämmanAktieägare som önskar delta i bolagsstämman ska: dels vara registrerad i eget namn (inte förvaltarregistrerad) i den av Euroclear Sweden AB förda aktieboken onsdagen den 14 februari 2024, dels anmäla sitt deltagande så att anmälan är Bolaget tillhanda senast fredagen den 16

About us

Nanologica is a Swedish life science tools company that develops, manufactures, and sells advanced consumables to pharmaceutical manufacturers. Nanologica’s products are specially developed for the purification of peptide drugs, such as insulin and GLP-1 analogues. Due to effective purification and a long lifetime for the products, they can increase productivity and reduce costs for pharmaceutical manufacturers. Nanologica operates in a global niche market that is growing as a result of increased demand for drugs for the treatment of diabetes and obesity. The company’s mission is to increase access to cost-effective drugs through its purification products and thereby contribute to more patients around the world having access to life-saving treatments. The company is headquartered in Södertälje and Nanologica’s share (NICA) is listed for trading on Nasdaq Stockholm Main Market.